EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Oct. 31, 2016--
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and
in vitro diagnostic technologies to the healthcare industry, announced
the launch of a single-coat formulation of its most advanced hydrophilic
medical device coating, Serene® solutions. Specifically
formulated for individual medical device applications, Serene
Single-Coat (SC) solutions allow manufacturers to leverage their legacy
coating process to apply this surface treatment.
Surmodics’ Serene coatings help device manufacturers meet the
challenge of achieving the right balance of lubricity (reduction in
friction) and durability for intravascular products. Surmodics continues
to lead the way with significant advances in coating formulations,
achieving low friction and low-particulate generation with the latest
formulation of Serene SC coating, that meet manufacturer’s
current processes to accelerate development and meet customer needs.
“With regulatory attention increasingly focused on lowering
particulates, we’ve experienced quick adoption of Serene coatings
among manufacturers already equipped for a two-coat process,” said Gary
Maharaj, president and chief executive officer. “Serene SC
solutions will broaden the range of medical device companies able to
benefit from the unmatched lubricity and durability this product family
provides.”
Hydrophilic coatings continue to be a critical design input to help
medical devices navigate tortuous vascular pathways. Hydrophilic
coatings reduce risk of damage to blood vessel walls and allow
physicians to reach distal treatment sites for procedures for improved
therapeutic outcomes.
About Serene Coating Solutions
The Surmodics family of Serene hydrophilic coatings combine
unmatched lubricity and durability, including dramatically improved
particulate reduction. Serene hydrophilic coatings bond to a wide
variety of substrates and have a proven regulatory record with leading
coronary, peripheral, neurovascular and structural heart devices.
Serene coatings are applied using Surmodics’ patented Photolink®
UV curing process, which covalently bonds surface treatments to
substrates at ambient temperature. This flexible technology can easily
be incorporated into existing manufacturing processes, and can markedly
reduce production time and reagent costs compared to both thermal-curing
and alternative light-activated processes.
About Surmodics, Inc.
Surmodics is the global leader in surface modification technologies for
intravascular medical devices and a leading provider of chemical
components for in vitro diagnostic (IVD) tests and microarrays.
Following two recent acquisitions of Creagh Medical and NorMedix, the
company is executing a key growth strategy for its medical device
business by expanding to offer total intravascular product solutions to
its medical device customers. The combination of proprietary surface
technologies, along with enhanced device design, development and
manufacturing capabilities, enables Surmodics to significantly increase
the value it offers with highly differentiated intravascular solutions
designed and engineered to meet the most demanding requirements. With
this focus on offering total product solutions, Surmodics’ mission
remains to improve the detection and treatment of disease by using its
technology to provide solutions to difficult medical device and
diagnostic challenges. Surmodics is headquartered in Eden Prairie,
Minnesota. For more information, visit www.surmodics.com.
The content of Surmodics’ website is not part of this press release or
part of any filings that the company makes with the SEC.
Serene® is a registered trademark of Surmodics, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161031005382/en/
Source: Surmodics, Inc.
Surmodics, Inc.
Andy LaFrence, 952-500-7000
Vice President of
Finance and Information Systems and Chief Financial Officer
